A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases

Expert Opinion on Pharmacotherapy
C BorghiEttore Ambrosioni

Abstract

Based on preclinical and clinical findings, zofenopril appears to be an angiotensin-converting enzyme (ACE) inhibitor with high potency, significant tissue selectivity and a long duration of action. Its ancillary properties, such as antioxidant activity and cardiovascular (CV) protection, make this drug potentially suitable for the treatment, and possibly prevention, of several CV diseases. There is a large body of evidence that support a complex interaction between ACE inhibitors and CV disease. A review of the preclinical profile of zofenopril clearly suggest that such interaction can be even more complex and could involve some drug-specific properties directly involved in the definition of the overall clinical profile of zofenopril as emerged from randomised clinical trials. In particular, zofenopril combines the feature of an effective ACE inhibitor, with plasma and tissue activity, along with that of an antioxidant compound, and both these characteristics can contribute to its capacity of controlling hypertension and improving the prognosis of patients with coronary artery disease. The results of The Survival of Myocardial Infarction Long term Evaluation (SMILE) trials have demonstrated that the early administration of zof...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jun 1, 1989·Journal of Cardiovascular Pharmacology·J M DeForrestE W Petrillo
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Feb 2, 2002·Blood Pressure·M G NichollsT Inagami
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 9, 2003·European Journal of Pharmacology·Anne Ward ScribnerClaudio Napoli

❮ Previous
Next ❯

Citations

Jun 18, 2014·Nature Reviews. Urology·Ersagun KaraguzelOmer Kutlu
Feb 28, 2007·Vascular Health and Risk Management·Claudio Borghi, Arrigo F G Cicero
Nov 4, 2006·Expert Review of Cardiovascular Therapy·Hendrik Buikema
Aug 23, 2006·American Heart Journal·Claudio BorghiUNKNOWN Survival of Myocardial Infarction Long-Term Evaluation Study
Sep 24, 2005·Journal of Pharmacological Sciences·Marie Eve MoreauAlbert Adam
Oct 7, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Donatella MutoloTito Pantaleo
Aug 8, 2014·Expert Review of Cardiovascular Therapy·Claudio Borghi, Stefano Omboni
May 19, 2020·Journal of the Science of Food and Agriculture·Jing DaiJianwei Mao
Dec 1, 2007·Blood Pressure. Supplement·Thomas HednerSverre E Kjeldsen
Feb 6, 2017·Blood Pressure·Claudio BorghiUNKNOWN : on behalf of the SMILE (Survival of Myocardial Infarction Long-term Evaluation) Working Project

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.